Researchers from the Dana-Farber Cancer Institute presented two posters at AACR 2017:
1. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids (abstract linked here)
2. Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids (abstract linked here)
1. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids (abstract linked here)
2. Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids (abstract linked here)
The researchers demonstrated that they could recapitulate sensitivity and innate resistance to PD-1 blockade ex vivo with an assay developed on AIM chips. They were able to profile the functional response to tumor PD-1 blockade ex vivo and unveil a novel strategy to advance precision immuno-oncology.
RSS Feed
